Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Original Article

    Growth Inhibitory Activity of Selected High Antioxidant Australian Syzygium Species Against the Food Poisoning and Tissue Necrotic Pathogen Clostridium Perfringens

    wadmin2By wadmin2January 5, 2016Updated:August 11, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Mitchell Henry Wright,1 Cameron Jay Lee,1 Charmaine Estelle Pollock,1 Anthony Carlson Greene,1 Ian Edwin Cock,1,2*
    1School of Natural Sciences, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, AUSTRALIA.
    2Environmental Futures Centre, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, AUSTRALIA.

    Pharmacognosy Communications,2016,6,2,93-99.
    DOI:10.5530/pc.2016.2.7
    Published: January 2016
    Type: Original Article

    ABSTRACT

    Introduction: Clostridium perfringens is a gram positive pathogen which is an etiological agent in Clostridial myonecrosis and enteritis necroticans. Unless promptly treated, C. perfringens infections may result in tissue necrosis and death. Syzygium australe (brush cherry) and Syzygium luehmannii (riberry) fruit and leaves have documented therapeutic properties as general antiseptic agents against an extensive panel of bacteria. Despite this, studies are yet to test the growth inhibitory activity of these species against C. perfringens. Methods: S. australe and S. luehmannii fruit and leaf extracts were investigated by disc diffusion assay for growth inhibitory activity against a clinical strain of Clostridium perfringens. Their MIC values were determined to quantify and compare their efficacies. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: Methanolic and aqueous S. australe and S. luehmannii fruit and leaf extracts as well as the corresponding fruit ethyl acetate extracts, displayed growth inhibitory activity in the disc diffusion assay against C. perfringens. The aqueous and methanolic extracts were particularly potent growth inhibitors, each with MIC values substantially <500 μg/mL. The S. australe fruit extracts were nontoxic in the Artemia franciscana bioassay (LC50 values <1000 μg/mL). All ethyl acetate extracts were also nontoxic. In contrast, the S. luehmannii aqueous and methanolic extracts (fruit and leaf), as well as the S. australe leaf extracts displayed substantial toxicity in the assay. Conclusion: The potent growth inhibitory bioactivity of the fruit and leaf aqueous and methanolic Syzygium spp. extracts against C. perfringens indicates their potential as medicinal agents in the treatment and prevention of clostridial myonecrosis and enteritis necroticans. 

    Key words: Syzygium australe, Syzygium luehmannii, Riberry, Brush cherry, antioxidant, Myonecrosis, Enteritis necroticans, Gas gangrene.
    Download PDF
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up